GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laboratorios Farmaceuticos Rovi SA (XMAD:ROVI) » Definitions » Cyclically Adjusted FCF per Share

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Cyclically Adjusted FCF per Share : €0.00 (As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Laboratorios Farmaceuticos Rovi Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Laboratorios Farmaceuticos Rovi's adjusted free cash flow per share for the three months ended in Mar. 2024 was €0.128. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €0.00 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Laboratorios Farmaceuticos Rovi's average Cyclically Adjusted FCF Growth Rate was 22.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Laboratorios Farmaceuticos Rovi was 275.60% per year. The lowest was 17.80% per year. And the median was 146.70% per year.

As of today (2024-06-04), Laboratorios Farmaceuticos Rovi's current stock price is €88.75. Laboratorios Farmaceuticos Rovi's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was €0.00. Laboratorios Farmaceuticos Rovi's Cyclically Adjusted Price-to-FCF of today is .

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Laboratorios Farmaceuticos Rovi was 2670.00. The lowest was 65.70. And the median was 170.45.


Laboratorios Farmaceuticos Rovi Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Laboratorios Farmaceuticos Rovi's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laboratorios Farmaceuticos Rovi Cyclically Adjusted FCF per Share Chart

Laboratorios Farmaceuticos Rovi Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 -0.01 0.18 0.53 0.65

Laboratorios Farmaceuticos Rovi Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.56 0.60 0.59 0.65 -

Competitive Comparison of Laboratorios Farmaceuticos Rovi's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Laboratorios Farmaceuticos Rovi's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laboratorios Farmaceuticos Rovi's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Cyclically Adjusted Price-to-FCF falls into.



Laboratorios Farmaceuticos Rovi Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Laboratorios Farmaceuticos Rovi's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.128/122.7621*122.7621
=0.128

Current CPI (Mar. 2024) = 122.7621.

Laboratorios Farmaceuticos Rovi Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.149 101.081 0.181
201409 0.052 100.441 0.064
201412 -0.138 100.251 -0.169
201503 0.019 99.474 0.023
201506 0.066 101.138 0.080
201509 -0.016 99.559 -0.020
201512 0.124 100.268 0.152
201603 0.237 98.638 0.295
201606 0.133 100.333 0.163
201609 0.099 99.737 0.122
201612 0.087 101.842 0.105
201703 -0.230 100.896 -0.280
201706 0.159 101.848 0.192
201709 0.025 101.524 0.030
201712 0.007 102.975 0.008
201803 0.021 102.122 0.025
201806 -0.141 104.165 -0.166
201809 -0.151 103.818 -0.179
201812 -0.083 104.193 -0.098
201903 -0.343 103.488 -0.407
201906 -0.008 104.612 -0.009
201909 -0.266 103.905 -0.314
201912 -0.277 105.015 -0.324
202003 -0.057 103.469 -0.068
202006 -0.346 104.254 -0.407
202009 0.014 103.521 0.017
202012 0.518 104.456 0.609
202103 0.376 104.857 0.440
202106 0.995 107.102 1.140
202109 0.723 107.669 0.824
202112 -0.136 111.298 -0.150
202203 1.892 115.153 2.017
202206 1.078 118.044 1.121
202209 -0.155 117.221 -0.162
202212 0.661 117.650 0.690
202303 0.374 118.948 0.386
202306 0.277 120.278 0.283
202309 -0.169 121.343 -0.171
202312 0.630 121.300 0.638
202403 0.128 122.762 0.128

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Laboratorios Farmaceuticos Rovi  (XMAD:ROVI) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Laboratorios Farmaceuticos Rovi was 2670.00. The lowest was 65.70. And the median was 170.45.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Laboratorios Farmaceuticos Rovi Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Laboratorios Farmaceuticos Rovi's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Business Description

Traded in Other Exchanges
Address
Julian Camarillo, 35, Madrid, ESP, 28037
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Headlines

From GuruFocus

Rovi Corp. (ROVI) President and CEO Alfred J Amoroso sells 200,000 Shares

By GuruFocus Research GuruFocus Editor 03-19-2011

Rovi Corp. (ROVI) President and CEO Alfred J Amoroso sells 96,461 Shares

By GuruFocus Research GuruFocus Editor 03-04-2011

Rovi Corp. (ROVI) EVP & CFO James Budge sells 10,833 Shares

By GuruFocus Research GuruFocus Editor 02-03-2011